Insider · CIK 0001308105
Russell Skibsted
Files at ALIM (ALIMERA SCIENCES INC), PCSA (Processa Pharmaceuticals, Inc.). First filing Apr 1, 2026, latest Jul 1, 2026.
In brief
Russell Skibsted files SEC Form 4 as CFO at PCSA (Processa Pharmaceuticals, Inc.), and also at ALIM (ALIMERA SCIENCES INC). Since Apr 1, 2026, Russell Skibsted has reported 7 open-market buys worth $42k and 0 open-market sells worth $0, the latest filed on Jul 1, 2026.
A track record needs three past buys with six months of prices behind them; Russell Skibsted has 0, so none is measured yet.
The newest scored trade: bought $6,325 of PCSA on Jun 30, 2026, filed Jul 1, 2026, scored 66 (notable). In the last 12 months: 7 buys worth $42k and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
PCSA: Processa Pharmaceuticals, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 66Notable | Processa Pharmaceuticals, Inc. | $6,325 3,277 shares | +24% | +4% from low-84% from high | |
| 56Moderate | Processa Pharmaceuticals, Inc. | $5,892 2,654 shares | +25% | +19% from low-82% from high | |
| 56Moderate | Processa Pharmaceuticals, Inc. | $5,890 2,292 shares | +27% | +38% from low-79% from high | |
| 56Moderate | Processa Pharmaceuticals, Inc. | $5,892 1,984 shares | +31% | +60% from low-75% from high | |
| 60Notable | Processa Pharmaceuticals, Inc. | $5,891 2,190 shares | +51% | +46% from low-77% from high | |
| 60Notable | Processa Pharmaceuticals, Inc. | $5,892 1,984 shares | +85% | +60% from low-75% from high | |
| 53Moderate | Processa Pharmaceuticals, Inc. | $5,891 2,324 shares | - | +36% from low-79% from high |
Transactions
Every row this insider has filed, 12 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 26, 2026 | PCSA Processa Pharmaceuticals, Inc. | AGrant or award Restricted Stock Unitsderivative | +11,883 | $0.00 | $0 | 17,323 | Jul 28, 2026 |
| Jun 30, 2026 | PCSA Processa Pharmaceuticals, Inc. | POpen-market purchase Common Stock | +3,277 | $1.93 | $6,325 | 16,689 | Jul 1, 2026 |
| Jun 15, 2026 | PCSA Processa Pharmaceuticals, Inc. | POpen-market purchase Common Stock | +2,654 | $2.22 | $5,892 | 13,412 | Jun 16, 2026 |
| May 29, 2026 | PCSA Processa Pharmaceuticals, Inc. | POpen-market purchase Common Stock | +2,292 | $2.57 | $5,890 | 10,758 | Jun 1, 2026 |
| May 15, 2026 | PCSA Processa Pharmaceuticals, Inc. | POpen-market purchase Common Stock | +1,984 | $2.97 | $5,892 | 8,466 | May 19, 2026 |
| Apr 30, 2026 | PCSA Processa Pharmaceuticals, Inc. | POpen-market purchase Common Stock | +2,190 | $2.69 | $5,891 | 6,498 | May 1, 2026 |
| Apr 15, 2026 | PCSA Processa Pharmaceuticals, Inc. | POpen-market purchase Common Stock | +1,984 | $2.97 | $5,892 | 4,308 | Apr 17, 2026 |
| Mar 31, 2026 | PCSA Processa Pharmaceuticals, Inc. | POpen-market purchase Common Stock | +2,324 | $2.54 | $5,891 | 2,324 | Apr 1, 2026 |
| Oct 1, 2025 | PCSA Processa Pharmaceuticals, Inc. | AGrant or award Restricted Stock Unitsderivative | +108,000 | $0.00 | $0 | 108,000 | Oct 3, 2025 |
| Oct 1, 2025 | PCSA Processa Pharmaceuticals, Inc. | AGrant or award Stock Options (Right to Buy)derivative | +324,000 | $0.00 | $0 | 324,000 | Oct 3, 2025 |
| Jul 24, 2025 | PCSA Processa Pharmaceuticals, Inc. | AGrant or award Restricted Stock Unitsderivative | +1,775,044 | $0.00 | $0 | 1,803,044 | Jul 28, 2025 |
| Nov 21, 2023 | ALIM ALIMERA SCIENCES INC | AGrant or award Employee Stock Option (Right to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Nov 28, 2023 |
Questions about Russell Skibsted
Answered from the filings on this page, as of the latest one.
Is Russell Skibsted buying or selling?
In the last 12 months Russell Skibsted reported 7 open-market buys worth $42k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $6,325 of PCSA on Jun 30, 2026. Grants, option exercises and tax withholding are not counted.
How did Russell Skibsted's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Russell Skibsted has 0.
Where does Russell Skibsted file Form 4?
Russell Skibsted has filed Form 4 at PCSA (Processa Pharmaceuticals, Inc.) as Chief Financial Officer; ALIM (ALIMERA SCIENCES INC) as Chief Financial Officer & SVP. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.